Early data from the phase II CHRYSALIS-2 trial was also presented at the 2022 ASCO meeting in which amivantamab was given in combination with the EGFR TKI, lazertinib, for patients with NSCLC who progressed on platinum-based chemotherapy and osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.